2019
DOI: 10.3389/fgene.2019.01152
|View full text |Cite
|
Sign up to set email alerts
|

RNA-Seq Perspectives to Improve Clinical Diagnosis

Abstract: In recent years, high-throughput next-generation sequencing technology has allowed a rapid increase in diagnostic capacity and precision through different bioinformatics processing algorithms, tools, and pipelines. The identification, annotation, and classification of sequence variants within different target regions are now considered a gold standard in clinical genetic diagnosis. However, this procedure lacks the ability to link regulatory events such as differential splicing to diseases. RNA-seq is necessar… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
59
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 81 publications
(63 citation statements)
references
References 64 publications
0
59
0
Order By: Relevance
“…The current methodology may serve as a template for the quantification of alternative splicing or of countless other mutations that bring about disease through aberrant splicing. Routine assessment of the latter, including the common thalassemic HBB IVSII−654(C > T) (HBB:c.316-197C > T) mutation [27], by conventional RT-PCR methods has limited utility, whereas assessments of splice events by targeted or global RNA-seq may impose unsuitable technical, cost or material requirements for many applications [28,29]. Adoption of the current assay would be simple and cost-effective and would allow clear conclusions on the regulation of alternative splicing or on the effect of therapeutic interventions, including pharmacological treatments, DNA editing or targeted mRNA knock-down, and on molecular mechanisms underlying their action.…”
Section: Discussionmentioning
confidence: 99%
“…The current methodology may serve as a template for the quantification of alternative splicing or of countless other mutations that bring about disease through aberrant splicing. Routine assessment of the latter, including the common thalassemic HBB IVSII−654(C > T) (HBB:c.316-197C > T) mutation [27], by conventional RT-PCR methods has limited utility, whereas assessments of splice events by targeted or global RNA-seq may impose unsuitable technical, cost or material requirements for many applications [28,29]. Adoption of the current assay would be simple and cost-effective and would allow clear conclusions on the regulation of alternative splicing or on the effect of therapeutic interventions, including pharmacological treatments, DNA editing or targeted mRNA knock-down, and on molecular mechanisms underlying their action.…”
Section: Discussionmentioning
confidence: 99%
“…In clinical genetics there are still many cases where a diagnosis cannot be made 20 . For some of these undiagnosed cases, RNA-Sequencing can help make a diagnosis 21 , and outlier ASE has recently been used as diagnostic tool for muscular disease patients 22 . However, to know what effect a very rare pathogenic variant might have, ASE must be analysed in a large dataset.…”
Section: Discussionmentioning
confidence: 99%
“…RNA sequencing (RNA-Seq) can be used to investigate differences in gene expression at a genome-wide level. RNA-Seq has the advantages of more accurate quantification, higher repeatability, a wider detection range, and more reliable analysis than other methods [18]. In addition to analyzing gene expression levels, RNA-Seq can also be used to discover new transcripts, single nucleotide polymorphisms (SNPs), and splice variants to provide information about allele-specific gene expression [23].…”
Section: Introductionmentioning
confidence: 99%